© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Advocates Emphasize Need for Patient Cost Savings From Biosimilars
Kelly Davio
September 13 2017
AAM Biosimilars Council Conference
On Tuesday, leaders of patient advocacy groups presenting at the 2017 AAM Biosimilars Council Conference had a clear message for industry: biosimilar uptake will only happen in earnest when patients begin to see savings on their out-of-pocket treatment costs.
Ten Years of Clinical Experience With Biosimilar Epoetin Alfa HX575
Jackie Syrop
September 12 2017
The epoetin alfa biosimilar HX575 (Binocrit, a product of Sandoz) was approved in the European Union in 2007 for the treatment of chemotherapy-induced anemia (CIA) and anemia associated with chronic renal failure.
AAM Executive: 1.2 Million Will Gain Treatment Access Because of Biosimilars
Kelly Davio
September 12 2017
AAM Biosimilars Council Conference
Christine Simmon, senior vice president of policy and strategic alliances for the Association for Accessible Medicines (AAM) and executive director of The Biosimilars Council, told The Center for Biosimilars® at the 2017 AAM Biosimilars Council Conference that upcoming product approvals in the biosimilar space are exciting prospects not only for the industry, but, most importantly, for patients.
Research Highlights Filgrastim and Pegfilgrastim Biosimilars
Jackie Syrop
September 11 2017
Three posters presented on September 10, 2017, at the European Society for Medical Oncology (ESMO) 2017 meeting in Madrid, Spain, covered research on 2 proposed pegfilgrastim biosimilars and evaluated the use of filgrastim in oncology practice.
Exhibit Caution When Interpreting PFS, OS Data in Biosimilarity Studies
The Center for Biosimilars Staff
September 9 2017
Oncology trials often report on progression-free survival or overall survival, but the authors of an analysis presented during a poster session today at the European Society of Medical Oncology (ESMO) Congress argue that such endpoints are less sensitive then short-term overall response rate.
Biosimilar Insulin Glargine Shows Pharmacokinetic and Pharmacodynamic Equivalence to the Originator
Jackie Syrop
June 15 2017
The study pesented at the American Diabetes Association 77th Scientific Sessions compared Mylan/Biocon’s MYL-1501D, a proposed biosimilar to Sanofi-Aventis’ insulin glargine, with the reference product.
Study Finds Significant Differences in Glycemic Control Between Reference and Biosimilar Morning Insulin
Kelly Davio
June 14 2017
In order to investigate the best morning insulin therapy to improve glycemic variability in patients with type 2 diabetes, researchers from Japan compared morning injections of insulin glulisine and insulin glargine with injections of insulin lispro and insulin glargine biosimilar.
Patients Switched Between Biosimilar and Reference Filgrastim With No Clinically Meaningful Difference
Kelly Davio
June 9 2017
A study presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) found that there was no clinically meaningful difference when patients with breast cancer were switched from treatment with reference filgrastim (Neupogen) to EP2006, the first FDA-approved filgrastim biosimilar (marketed as Zarxio).
CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference
Kelly Davio
June 8 2017
Research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) shows that CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2–positive early breast cancer.